Search database
LIST OPTIONS
Filter
45
Filtered Results: 45
Text search: Covishield
Featured
Language
Document type
Guidelines
19
Fact sheets
10
Manuals
6
Studies & Reports
6
Situation Updates
2
Resource Platforms
1
Strategic & Response Plan
1
Countries / Regions
Argentina
12
Brazil
4
India
3
Latin America and the Carribbean
2
Ukraine
1
Syria
1
West and Central Africa
1
East and Southern Africa
1
South Sudan
1
Ecuador
1
Authors & Publishers
World Health Organization WHO
14
Ministerio de Salud Argentina
9
Dirección de Control de Enfermedades Inmunoprevenibles
4
Feraud, H.
4
Africa CDC Centres for Disease Control and Prevention
3
African Union
3
Organización Mundial de la Salud OMS
3
Pan American Health Organisation PAHO
3
OPAS
2
World Health Organization WHO, Regional Office of Europe
2
Coision Nacional de Seguridad en Vacunas
1
Eastern Mediterranean Region
1
Ministerio da Saude do Brasil
1
Ministerio de Salud Pública de Ecuador
1
Ministerio de Salud, Argentina
1
Ministry of Health& Family Welfare, Goverment of India
1
OPAS, OMS
1
OPS
1
Organisation mondiale de la Santé OMS
1
Organización Panamericana de la Salud
1
Organização Mundial da Saúde (OMS)
1
PAHO
1
WHO
1
World Health Organisation (WHO)
1
World Health Organization WHO, Regional Office of Africa
1
World Health Organization WHO, SAGE
1
Publication Years
Category
Countries
25
Clinical Guidelines
2
Toolboxes
COVID-19
42
Conflict
2
Refugee
1
Recommendations for the adaptation of Emergency Medical Teams (EMTs) at temporary sites for COVID-19 vaccination. Draft Version 2.3, November 2021
Emergency medical teams (EMTs) play an important role in strengthening health service networks in terms of their strategies and tactics for planning mass vaccination programs, especially in remote or under-resourced areas or those overwhelmed by COVID-19. EMTs experience deploying in remote areas an... more
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato... more
interim guidance, 14 June 2021 This document is intended for national authorities and decision makers in countries that have introduced large scale public health and social measures. It offers guidance for adjusting public health and social measures, while managing the risk of a resurgence of cases... more
El siguiente manual se continuará actualizando, de ser necesario, a medida que se disponga de nueva información.
Overview 16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
Vaccinator's Manual. CONVIDECIA Vaccine
orientations provisoires, 14 juin 2021
orientaciones provisionales, 14 de junio de 2021
Considerations on the implementation and adjustment of public health and social measures in the context of COVID-19 Interim guidance 14 June 2021
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de... more
interim guidance, 19 July 2021 (arabic version)
Campaña Nacional de Vacunación contra la COVID-19
This document provides guidance on interventions to prevent vaccine-preventable disease outbreaks in the context of mass population movement resulting from the ongoing crisis in Ukraine.
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab... more
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards the Immunization Agenda 2030 and pandemic prevention, preparedness and response efforts. The report is organized i... more
COVID-19 Situation Update OPS/WHO Argentina: 10 February 2022 Situation report generated by the OPS/WHO representation in Argentina